A new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute demonstrated that RNA nanoparticles have elastic and rubbery properties.
A study published in the Journal of the National Comprehensive Cancer Network adds important knowledge about how immunotherapy-related adverse events can impact more than one organ in a single patient.
City of Hope scientists have combined two immunotherapies—an oncolytic virus and chimeric antigen receptor CAR T-cell therapy—to target and eradicate solid tumors that are otherwise difficult to treat with CAR T therapy alone, according to a study in Science Translational Medicine.
Data from the pivotal GEOMETRY mono-1 phase II study show treatment with Tabrecta (capmatinib, formerly INC280) resulted in positive overall response rates among adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to skipping of MET exon 14. Positive duration of response was also observed.
Data from the National Coalition for Cancer Survivorship's 2020 State of Cancer Survivorship Survey show that cancer survivors are likely to rely on their doctor to tell them what treatment option is best.
The phase III VIALE-A clinical trial evaluating newly-diagnosed AML patients who had not yet been treated and were unable to tolerate traditional intensive chemotherapy, found that venetoclax in combination with azacitidine extended overall survival compared to azacitidine plus placebo.
Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a significant improvement in overall survival in patients with previously untreated, unresectable malignant pleural mesothelioma in the phase III CheckMate -743 clinical trial.
CheckMate -649, a pivotal phase III trial evaluating Opdivo plus chemotherapy compared to chemotherapy alone as a first-line treatment for metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, met both primary endpoints of overall survival at a pre-specified interim analysis and progression-free survival at final analysis in patients whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.
The phase III CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer met its primary endpoint of disease-free survival at a pre-specified interim analysis.
The phase III IMpassion131 study evaluating Tecentriq in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival for the initial (first-line) treatment of people with metastatic triple-negative breast cancer, in the PD-L1-positive population.
